**Author details**

Nazanin Karimnia1,2, Gwo-Yaw Ho3,4, Andrew N. Stephens1,2 and Maree Bilandzic1,2\*

1 Hudson Institute of Medical Research, Clayton, VIC, Australia

2 Department of Molecular and Translational Sciences, Monash University, Clayton, VIC, Australia

3 School of Clinical Sciences, Monash University, Clayton, VIC, Australia

4 Monash Health, Clayton, VIC, Australia

\*Address all correspondence to: maree.bilandzic@hudson.org.au

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**151**

*Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option*

carcinomas: an exception to the norm. Journal of cellular physiology **213**,

[10] Kalluri, R. & Weinberg, R.A. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation **119**, 1420-1428 (2009).

[11] Patel Ila, S., Madan, P., Getsios, S., Bertrand Monique, A. & MacCalman Colin, D. Cadherin switching in ovarian cancer progression. International Journal of Cancer **106**, 172-177 (2003).

[12] Wintzell, M., Hjerpe, E., Åvall Lundqvist, E. & Shoshan, M. Protein markers of cancer-associated fibroblasts

and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer **12**,

[13] Mitra, A.K. Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination, Tumor Metastasis in *Tumor Metastasis* (InTechOpen, 2016).

[14] Ahmed, N., Abubaker, K., Findlay, J. & Quinn, M. Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance. Journal of Cellular Biochemistry **114**, 21-34 (2013).

[15] Bapat, S.A., Mali, A.M., Koppikar,

C.B. & Kurrey, N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer research **65**,

[16] Kenny Hilary, A., Krausz, T.,

Yamada Seiko, D. & Lengyel, E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. International Journal of Cancer **121**, 1463-1472 (2007).

[17] Kenny, H.A., Krausz, T., Yamada, S.D. & Lengyel, E. Use of a novel 3D

581 (2007).

359 (2012).

3025 (2005).

*DOI: http://dx.doi.org/10.5772/intechopen.98689*

[1] Torre, L.A.*, et al.* Ovarian cancer statistics, 2018. CA Cancer J Clin **68**,

[2] Ahmed, N. & Stenvers, K.L. Getting

[3] Garrison, N.R., Kaelin, D.L., Heuser, S.L. & Galloway, H.R. Malignant Ascites: Clinical and Experimental Observations. Annals of Surgery **203**,

[4] Adam, R.A. & Adam, Y.G. Malignant ascites: past, present, and future. Journal of the American College of Surgeons **198**, 999-1011 (2004).

[5] Feldman, G.B. & Knapp, R.C. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. American journal of obstetrics and gynecology **119**, 991 (1974).

[6] Yeung, T.-L.*, et al.* Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. American journal of physiology. Cell physiology **309**,

[7] Pradeep, S.*, et al.* Hematogenous Metastasis of Ovarian Cancer:

[8] Carmignani, C., Sugarbaker, T., Bromley, C. & Sugarbaker, P.

[9] Ahmed, N., Thompson, E.W. & Quinn, M.A. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian

Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer and Metastasis Reviews **22**,

Rethinking Mode of Spread. Cancer Cell

to know ovarian cancer ascites: opportunities for targeted therapybased translational research. Frontiers

in oncology **3**, 256 (2013).

**References**

284-296 (2018).

644-651 (1986).

C444 (2015).

**26**(2014).

465-472 (2003).

*Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option DOI: http://dx.doi.org/10.5772/intechopen.98689*
